|
|
Article: NEW NASAL SPRAY TREATMENT FOR POSTMENOPAUSAL OSTEOPOROSIS
- Article from:
- PR Newswire
- Article date:
- August 18, 1995
CopyrightCOPYRIGHT 1995 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
EAST HANOVER, N.J., Aug. 18 /PRNewswire/ -- Sandoz Pharmaceuticals Corporation announced today that it has received clearance to market MIACALCIN(R) Nasal Spray (calcitonin-salmon) for the treatment of postmenopausal osteoporosis. Widening the therapeutic options for a crippling and sometimes life-threatening bone disease affecting more than 20 million American women, MIACALCIN Nasal Spray offers a new approach in the delivery of osteoporosis therapy. Clinical studies with MIACALCIN Nasal Spray have shown significant increases in spinal bone mineral density in women more than five years after menopause.
"While estrogens are considered first line therapy for ...